Daily Washington Insider
  • Business
  • World
  • Science
  • Investing

Daily Washington Insider

  • Business
  • World
  • Science
  • Investing
Business

Johnson & Johnson to pay $6.5 billion to resolve nearly all talc ovarian cancer lawsuits in U.S.

by admin May 6, 2024
May 6, 2024
Johnson & Johnson to pay $6.5 billion to resolve nearly all talc ovarian cancer lawsuits in U.S.

Johnson & Johnson on Wednesday said it plans to pay $6.5 billion over 25 years to settle nearly all of the thousands of lawsuits in the U.S. claiming its talc-based products caused ovarian cancer, pending approval of the claimants.

Those cases have for decades caused financial and public relations trouble for J&J, which contends that its now-discontinued talc baby powder and other talc products are safe for consumers. About 99% of the talc-related lawsuits filed against J&J and its subsidiaries stem from ovarian cancer. 

The company recorded a charge of about $2.7 billion in the first quarter to raise its reserve for talc claims to about $11 billion.

The deal, pending approval by claimants, would allow J&J to resolve the lawsuits through a third bankruptcy filing of a subsidiary company, LTL Management. Courts have rebuffed J&J’s two previous efforts to resolve the lawsuits through the bankruptcy of that subsidiary, which was created to absorb the company’s talc liabilities.

J&J will begin a three-month voting period for claimants, in hopes of reaching a 75% support threshold needed for a bankruptcy settlement that would end the litigation entirely and prevent future lawsuits. Claimants did not have the opportunity to vote in LTL Management’s previous bankruptcy cases, J&J executives said on a call with investors on Wednesday.

J&J has the “significant support of the overwhelming majority of the claimants” based on conversations with their lawyers or representation, the executives added.

“We firmly believe this plan is in the best interest of claimants and should receive a favorable and immediate confirmation from the bankruptcy court,” said Erik Haas, J&J’s worldwide vice president of litigation, during the call.

He contended the settlement is a far better recovery for claimants than would be likely in a trial.

“As that track record shows, most of bearing claimants have not recovered, nor are they expected to ever recover anything at trial,” Haas said. “At the rate at which use cases have been tried, it would take decades to try the remaining cases meaning most claimants will never see their day in court.”

Still, litigation has resulted in some large verdicts for claimants. That includes a roughly $2 billion award in favor of 22 women who blamed their ovarian cancer on asbestos in J&J’s talc products.

Shares of J&J rose more than 2% in premarket trading Wednesday.

J&J said the remaining pending lawsuits relate to a rare cancer called mesothelioma and will be addressed outside of the new settlement plan. The pharmaceutical giant said it has already resolved 95% of mesothelioma lawsuits filed to date.

J&J noted on Wednesday that it has reached “final and comprehensive” settlements to resolve an investigation by a coalition of more than 40 states into claims the company misled patients about the safety of its talc baby powder and other talc-based products.

The company has also reached an agreement in principle to resolve claims brought by suppliers of its talc, which include Imerys Talc America, Cyprus Mines Corporation and their related parties.

This post appeared first on NBC NEWS

0
FacebookTwitterGoogle +Pinterest
previous post
Israel to close Al Jazeera news network in the country
next post
Johnson & Johnson to pay $6.5 billion to resolve nearly all talc ovarian cancer lawsuits in U.S.

You may also like

Former MGM Grand casino president to be sentenced...

May 9, 2024

Some Walmart garment orders from Bangladesh on hold...

July 14, 2025

UPS shares tank 15% after weak guidance, plan...

February 1, 2025

Trump could scale back Canada, Mexico tariffs Wednesday,...

March 6, 2025

Charlie Javice sentenced to 7 years in prison...

October 1, 2025

Home Depot earnings beat Wall Street estimates as...

February 27, 2025

Procter & Gamble to cut 7,000 jobs as...

June 9, 2025

OpenAI introduces Operator to automate tasks like vacation...

January 24, 2025

Family offices are giving top staff equity, profit...

July 31, 2024

McDonald’s preparing a 2025 ‘McValue’ offering

November 22, 2024

    Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Popular

    • 1

      Hong Kong plans to install thousands of surveillance cameras. Critics say it’s...

    • 2

      UN experts urge Thailand not to deport dozens of Uyghurs to China where they face ‘real risk of torture’

    • 3

      China executes man who plowed car into crowds in deadliest attack in a decade

    • 4

      Trump has assembled a team of China hawks. How will Beijing respond?

    • 5

      How Calvin Klein and Tommy Hilfiger got caught in Trump’s trade war with China

    Categories

    • Business (1,338)
    • Investing (3,655)
    • Science (605)
    • World (3,677)
    Footer Logo

    Disclaimer: dailywashingtoninsider.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2024 dailywashingtoninsider.com | All Rights Reserved